Janux Therapeutics (JANX) risk factors, FY2025 10-K

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 01We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it
2. 02If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations68% rewritten
3. 03will need to raise substantial additional capital to complete the development and commercialization of our product candidatesNew
4. 04the costs of operating as a public company
5. 05Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

1. 06We are early in our development efforts and all of our product candidates and research programs other than JANX007 and JANX008 are in the preclinical development or discovery stage. We have a limited history of conducting clinical trials to test our product candidates in humans
2. 07maintaining a continued acceptable safety profile of any product following approval, if any
3. 08manufacturing sufficient quantities of product candidate for use in clinical trials
4. 09Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval
5. 10If we experience delays in or difficulties enrolling our ongoing and planned clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected
6. 11the risk that patients enrolled in clinical trials will drop out of the trials before completion
7. 12Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates
8. 13risks, until such time as we complete large-scale human trials there can be no assurances that our product candidates will not experience similar effects
9. 14Interim, topline and preliminary data from our preclinical studies or clinical trials may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data
10. 15the potential for approval policies or regulations of the FDA, the European Commission or comparable foreign regulatory authorities’ to significantly change in a manner rendering our clinical data insufficient for approval
11. 16requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization
12. 17If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could harm our business, financial condition, results of operations and prospects89% rewritten
13. 18We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
14. 19We may not be successful in our efforts to identify or discover additional product candidates in the future
15. 20potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance

Risks Related to Manufacturing, Commercialization and Reliance on Third Parties

1. 21We contract with third parties for the manufacturing and supply of certain of our product candidates for use in preclinical testing and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity20% rewritten
2. 22in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates28% rewritten
3. 23derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contaminationNew
4. 24Changes in methods of product candidate manufacturing may result in additional costs or delays
5. 25Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success
6. 26We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably47% rewritten
7. 27neither experimental nor investigational
8. 28Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
9. 29Relevant regulatory exclusivities may not be granted or, if granted, may be limited
10. 30The market opportunity for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate
11. 31Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
12. 32unforeseen costs and expenses associated with creating an independent sales and marketing organization
13. 33Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential

Risks Related to Our Collaborations and Other Strategic Agreements

1. 34We may not realize the benefits of any acquisitions, collaborations, in-license or strategic alliances that we enter into
2. 35We may wish to form additional collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans

Risks Related to Our Industry and Business Operations

1. 36Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
2. 37diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations
3. 38decreased demand for our product candidates, if approved for commercial sale
4. 39We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
5. 40We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
6. 41improve our operational, financial and management controls, reporting systems and procedures
7. 42We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us
8. 43rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical
9. 44Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
10. 45Epidemic diseases could adversely impact our business, including our ongoing and planned clinical trials, supply chain and business development activities
11. 46These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition

Risks Related to Government Regulation

1. 47European Union and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers
2. 48Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates93% rewritten
3. 49In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and will remain in effect until 2032 unless additional Congressional action is takenNew
4. 50use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantagesNew
5. 51International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew
6. 52may continue to impose additional sanctions, such as trade restrictions or trade barriers, which could restrict us from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to our businessNew

Risks Related to Our Intellectual Property

1. 53We rely upon a combination of patents, know-how and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market64% rewritten
2. 54European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigationNew
3. 55We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable
4. 56whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries
5. 57Intellectual property rights do not necessarily address all potential threats to our competitive advantage
6. 58we may fail to adequately protect and police our trademarks and trade secrets; and
7. 59We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products44% rewritten
8. 60agreements and those being tested or approved in combination with such products. Such an occurrence could materially adversely affect the value of the product candidates being developed under any such agreementNew
9. 61the priority of invention of patented technology
10. 62In the future, we may need to obtain licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated
11. 63If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates
12. 64We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful
13. 65Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
14. 66We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
15. 67Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
16. 68Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
17. 69We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
18. 70We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
19. 71Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
20. 72If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

Risks Related to the Securities Market and Ownership of Our Common Stock

1. 73The price of our common stock could be subject to volatility related or unrelated to our operations
2. 74any other factors discussed in this Annual Report37% rewritten
3. 75Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
4. 76If there are substantial sales of shares of our common stock, the market price of our common stock could decline28% rewritten
5. 77Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
6. 78Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
7. 79We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to public company reporting and compliance initiatives50% rewritten
8. 80to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipateNew
9. 81If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired
10. 82Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud67% rewritten
11. 83Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations
12. 84Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations66% rewritten
13. 85Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
14. 86Inflation may adversely affect us by increasing our costs
15. 87We or the third parties upon whom we depend on may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
16. 88If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
17. 89We may not be able to protect our intellectual property rights throughout the world51% rewritten
18. 90at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any such lawsuits that we initiate and the damages and other remedies awarded, if any, may not be commercially meaningfulNew
19. 91If securities or industry analysts cease to publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
20. 92Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
21. 93We could be subject to securities class action litigation